Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Nov 2022 | From Akero Therapeutics

Efruxifermin, a bivalent Fc-FGF21 analog, demonstrates improved biophysical and pharmacological engagement with live cells compared to monovalent FGF21 analogs

Aug 2022 | From Akero Therapeutics

Normalization of liver fat by efruxifermin is associated with improved liver, adipose tissue, and whole-body metabolic health

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis in NASH patients across PNPLA3 genotypes: a post hoc analysis of the Ph2a BALANCED study

Jun 2022 | From Akero Therapeutics

Efruxifermin (EFX), a long-acting FGF21 analog as a therapy for NASH

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment significantly reduced markers of collagen synthesis and fibrosis and normalized levels of Pro-C3 in patients with livery fibrosis associated with NASH

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.